Physician profile
Daniel M Wik
NPI 1093752883
$8,163.27
in general payments reported to CMS, 2019-2025
42 companies · $90.50 in 2025
The $90.50 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,787 · 2020: $682 · 2021: $1,155 · 2022: $1,240 · 2023: $191 · 2024: $17.37 · 2025: $90.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $3,886.75 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $519.22 | 2019-2021 | |
| Boston Scientific Corporation | $385.00 | 2019-2022 | |
| Lilly USA, LLC | $311.13 | 2019-2023 | Emgality |
| Abbvie INC. | $279.16 | 2021-2023 | Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $258.78 | 2021 | |
| Collegium Pharmaceutical, INC. | $232.20 | 2019-2023 | Xtampza |
| Biohaven Pharmaceutical Holding Company Ltd. | $214.33 | 2022 | |
| Grt US Holding, INC. | $201.87 | 2020-2022 | |
| Stimwave Technologies Incorporated | $197.28 | 2019-2022 | |
| Amgen INC. | $191.39 | 2019-2022 | |
| Novo Nordisk INC | $167.45 | 2019-2022 | |
| Allergan, INC. | $122.97 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $107.55 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $100.39 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.